RET and non-small cell lung carcinoma: (64) conducted a phase II clinical trial in which 18 patients with RET fusion-positive metastatic or recurrent NSCLC who previously received and responded to platinum-based doublet chemotherapy were recruited between July 2013 and October 2015.